CagriSema meta-analysis of 8 randomized trials and 6,898 adults reports greater weight loss than semaglutide
A systematic review and pairwise meta-analysis of eight randomized controlled trials in 6,898 adults reports larger body weight and HbA1c reductions with CagriSema than with semaglutide, cagrilintide, or placebo, alongside more adverse events.
Diabetes, metabolic syndrome and obesity : targets and therapy · 2026 · Meta-analysis · n=6898 · Human · Published October 1, 2026
This page reports what published studies found. It is not medical advice, no provider-patient relationship is created by reading it, and nothing here is a recommendation to use any compound. Talk with a licensed clinician about your own situation. Read the full disclaimer.
What the study did
This is a systematic review and pairwise meta-analysis of randomized controlled trials in humans; the authors report that eight RCTs comprising 6,898 participants were included. The stated aim was to evaluate the efficacy and safety of the dual-agonist combination CagriSema against semaglutide monotherapy, cagrilintide monotherapy, and placebo in adults with overweight or obese status and type 2 diabetes.
According to the abstract, the authors searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials, and separate pairwise meta-analyses were conducted using random effects models.
What it reported
The authors report that CagriSema was associated with significantly greater percentage body weight reduction compared to semaglutide (mean difference -6.60%, 95% CI -8.51 to -4.68), cagrilintide (-8.15%, 95% CI -11.40 to -4.89), and placebo (-14.30%, 95% CI -17.41 to -11.19), each with P<0.0001. A greater decrease in the percentage of glycated hemoglobin was also reported for CagriSema than for each comparator.
The abstract further states that CagriSema achieved greater reductions in absolute body weight, waist circumference, and body mass index across all comparators, demonstrated better blood pressure control compared with cagrilintide and placebo with effects comparable to semaglutide, and decreased C-reactive protein and improved lipid profiles compared with cagrilintide and placebo.
On safety, the authors report that CagriSema increased any adverse events and gastrointestinal adverse events compared with all comparators. The abstract does not report the dosing regimens used in the pooled trials.
Limitations
The authors name two key limitations: the relatively small number of eligible trials and the current lack of long-term cardiovascular endpoints. They also report substantial statistical heterogeneity in several continuous outcomes, which they attribute to diverse baseline clinical characteristics and background therapies; several pooled estimates carry I-squared values above 90%.
Structurally, this is a pooled analysis rather than a new trial, so its findings are limited by the design, duration, and reporting of the included studies. The abstract does not state the dose regimens, trial durations, funding sources, or author affiliations, and no individual-participant data are described.
Regulatory context
Cagrilintide, also referred to as AM833 or NNC0174-0833 and coformulated with semaglutide as CagriSema, is not an FDA-approved drug for any use. This status comes from the site's regulatory review, not from the meta-analysis described here.
Claims and where they come from
Each statement below is followed by the passage of the source record it was checked against.
The pooled analysis included eight randomized controlled trials with 6,898 participants.
“Eight RCTs comprising 6898 participants were included.”
The authors searched four databases through 14 June 2026 for randomized controlled trials.
“we searched Embase, MEDLINE, PubMed, and the Cochrane Library up to 14 June 2026 for randomized controlled trials (RCTs)”
CagriSema was associated with a greater percentage body weight reduction than semaglutide in the pooled estimate.
“CagriSema was associated with significantly greater percentage body weight reduction compared to semaglutide [MD -6.60%; 95%CI: -8.51 to -4.68; P<0.0001; I 2 =82%]”
Blood pressure control with CagriSema was reported as better than cagrilintide and placebo and comparable to semaglutide.
“CagriSema demonstrated better blood pressure control compared with cagrilintide and placebo, with effects comparable to those of semaglutide.”
Adverse events, including gastrointestinal events, were more frequent with CagriSema than with all comparators.
“CagriSema increased any adverse events and gastrointestinal adverse events compared with all comparators.”
The authors cite few eligible trials and absent long-term cardiovascular endpoints as key limitations.
“Key limitations include the relatively small number of eligible trials and the current lack of long-term cardiovascular endpoints.”
Common questions
Does the abstract state what doses were used?
No. The abstract reports comparisons of CagriSema against semaglutide, cagrilintide, and placebo but does not state the dose amounts, routes, or schedules used in the pooled trials.
Was this a new clinical trial?
No. It is a systematic review and pairwise meta-analysis that pooled eight previously conducted randomized controlled trials totaling 6,898 participants, using random effects models.
What safety findings were reported?
The authors report that CagriSema increased any adverse events and gastrointestinal adverse events compared with all comparators. The abstract gives no numerical rates for these events.
Were cardiovascular outcomes assessed?
The authors state that a current lack of long-term cardiovascular endpoints is one of the key limitations of the available evidence they pooled.
Source
- 1.Efficacy and Safety of CagriSema for Metabolic Outcomes: Systematic Review and Pairwise Meta-Analysis of Randomized Controlled Trials — Diabetes, metabolic syndrome and obesity : targets and therapy (2026)Meta-analysishumann=6898PMID 42763732DOI 10.2147/dmso.s616418